VALOR-HCM

pharma-biotechhealthcare-services

Is this you? Claim this profile →

No public contact links on file.

Speaking history

Basic Cardiovascular Sciences Scientific Sessions

13 July 2026 Boston, United States “VALOR-HCM - Mavacamten Treatment in Patients with Obstructive HCM Referred for Septal Reduction Therapy: 128-Week Results from VALOR-HCM Trial”

Topics this speaker covers

pharma-biotechhealthcare-services

Sectors

healthcare_medtech_pharma

Sourcing speakers for your event?

Browse the speaker directory →